Actively Recruiting
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
Led by Novartis Pharmaceuticals · Updated on 2026-03-24
108
Participants Needed
23
Research Sites
151 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
CONDITIONS
Official Title
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18 - 60 years old (inclusive).
- History or presence of fever (≥ 38°C).
- At least one of the following indicating dengue infection: nausea or vomiting; rash; aches or pains including headache, muscle or joint pain.
- Onset of fever ≤ 48 hours prior to treatment start.
- Positive test for dengue fever.
You will not qualify if you...
- Any abnormalities in clinical laboratory parameters.
- Use of any anticoagulant drugs.
- Significant medical conditions or illnesses requiring other medications that may interact with the study drug.
- Pregnant or nursing (lactating) women.
- Severe dengue symptoms at screening based on WHO 2009 guidelines.
- Specific laboratory abnormalities at screening including hemoglobin <12.0 g/dL (males) or <11.0 g/dL (females), hematocrit >52% (males) or >46% (females), absolute neutrophil count <1500/µL, platelet count <80,000/mm3, creatinine >165 µmol/L (males) or >130 µmol/L (females), serum creatine kinase >600 U/L, ALT/AST levels more than 1.5 times upper limit of normal, total bilirubin >24 µmol/L.
- Use of proton pump inhibitors within 48 hours before screening.
- Women of child-bearing potential not using highly effective contraception during dosing and 4 days after stopping the drug.
- History of long-QT syndrome, significant ECG abnormalities, or QTcF >450 msec (males) or >460 msec (females) at screening.
- Other protocol-defined inclusion/exclusion criteria may apply.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 23 locations
1
Novartis Investigative Site
Manaus, Amazonas, Brazil, 69040-000
Actively Recruiting
2
Novartis Investigative Site
Brasília, Federal District, Brazil, 71635-580
Actively Recruiting
3
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil, 21040-360
Actively Recruiting
4
Novartis Investigative Site
Sorocaba, São Paulo, Brazil, 18040-425
Actively Recruiting
5
Novartis Investigative Site
Sao Jose Rio Preto, Brazil, 15090 000
Actively Recruiting
6
Novartis Investigative Site
Barranquilla, Atlántico, Colombia, 080012
Actively Recruiting
7
Novartis Investigative Site
Bucaramanga, Santander Department, Colombia, 681017
Actively Recruiting
8
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia, 760032
Actively Recruiting
9
Novartis Investigative Site
Belagavi, Karnataka, India, 590010
Actively Recruiting
10
Novartis Investigative Site
Mumbai, Maharashtra, India, 400008
Withdrawn
11
Novartis Investigative Site
Pune, Maharashtra, India, 411013
Actively Recruiting
12
Novartis Investigative Site
Jaipur, Rajasthan, India, 302017
Actively Recruiting
13
Novartis Investigative Site
Chennai, Tamil Nadu, India, 600113
Actively Recruiting
14
Novartis Investigative Site
Kuantan, Pahang, Malaysia, 25200
Actively Recruiting
15
Novartis Investigative Site
Ipoh, Perak, Malaysia, 30450
Actively Recruiting
16
Novartis Investigative Site
Seberang Jaya, Pulau Pinang, Malaysia, 13700
Actively Recruiting
17
Novartis Investigative Site
Miri, Sarawak, Malaysia, 98000
Actively Recruiting
18
Novartis Investigative Site
Kuala Selangor, Malaysia, 68000
Actively Recruiting
19
Novartis Investigative Site
Singapore, Singapore, 169608
Actively Recruiting
20
Novartis Investigative Site
Singapore, Singapore, S308433
Actively Recruiting
21
Novartis Investigative Site
Haiphong, Vietnam, 180000
Actively Recruiting
22
Novartis Investigative Site
Hanoi, Vietnam, 100000
Actively Recruiting
23
Novartis Investigative Site
Ho Chi Minh City, Vietnam, 700000
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here